According to Precedence Research, the global liquid biopsy market size will grow from USD 7.05 billion in 2025 to nearly USD ...

Bladder cancer is a painful and often recurring disease, not just for humans, but for our canine companions as well. Urothelial carcinoma, the most common type of bladder cancer, affects both species ...

Previously, research on controlling gene networks has been carried out based on a single stimulus-response of cells. More recently, studies have been proposed to precisely analyze complex gene ...

"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

A universal technology that identifies gene control targets within altered gene networks in cells and restores them to a normal state has been ...

Topline results from the IMvigor011 trial show that ctDNA-guided adjuvant atezolizumab improves survival in patients with MIBC. Adjuvant atezolizumab in patients who are ctDNA-positive after radical ...

Over Labor Day weekend college football season kicks off in earnest. But it can be argued that perhaps the 2025 campaign’s most heartwarming story has already been told. And it had nothing to do with ...

Sanders underwent surgery to remove the tumor and reconstruct his bladder, resulting in a "neobladder." He is now cancer-free but faces lifestyle adjustments and continues to advocate for health ...

Bladder cancer is mainly urothelial carcinoma, with non-muscle-invasive and muscle-invasive types, and smoking as a key risk factor. Diagnosis involves cystoscopy, biopsy, urine cytology, and imaging ...

The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for ...